Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency
Molecular Genetics & Genomic Medicine · 2024
DOI: 10.1002/mgg3.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2024. Verfasst von Yiming Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Quanzhou Maternity and Children's Hospital, Quanzhou, Fujian, China. Hauptthemen laut MEDLINE: Carnitine, Solute Carrier Family 22 Member 5, High-Throughput Nucleotide Sequencing, Hyperammonemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujian Provincial Society of Laboratory Medicine and National (Fujian) Genetic Testing Technology Application Demonstration Center, Quanzhou City Science and Technology Program of China, Joint Innovation Project of Huaqiao University.
Abstract (Originalsprache)
Background
Newborn screening (NBS) for primary carnitine deficiency (PCD) has poor performance. This study aimed to evaluate the feasibility of incorporating next‐generation sequencing (NGS) as a second‐tier PCD test.
Methods
Between March and December 2020, 60,070 newborns were screened for inherited metabolic disorders. Newborns with free carnitine (C0) levels below 8.5 μmol/L were selected for second‐tier genetic testing.
Results
In total, 130 (0.22%) newborns with low C0 levels underwent second‐tier genetic testing, 87 (66.92%) had positive genetic testing results, and 30 (23.08%) carried pathogenic variants of the SLC22A5 gene. Six newborns were diagnosed with PCD. The incidence of PCD was approximately 1 in 1:10,012 newborns. The PPV reached 20% after combining with second‐tier NGS. Of the eight variants identified in patients with PCD, the three most common variants were c.760C>T (p.Arg254*), c.51C>G (p.Phe17Leu), and c.1400C>G (p.Ser467Cys). The C0 levels of patients with PCD were significantly lower than those of PCD carriers ( p = 0.0026) and PCD‐negative individuals ( p = 0.0005).
Conclusions
Our results showed that the PPV reached 20% after combining with second‐tier NGS. The MS/MS‐based NBS and second‐tier NGS combination can effectively reduce the false‐positive rate and detect PCD in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Quanzhou Maternity and Children's Hospital, Quanzhou, Fujian, China.
- Neonatal Disease Screening Center, Quanzhou Maternity and Children's Hospital, Quanzhou, Fujian, China.
ORCID-Profile: Weilin Peng
Förderung
- Fujian Provincial Society of Laboratory Medicine and National (Fujian) Genetic Testing Technology Application Demonstration Center
- Quanzhou City Science and Technology Program of China
- Joint Innovation Project of Huaqiao University
Zitieren
APA
Lin, Y., Zheng, Z., Lin, W., & Peng, W. (2024). Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70003
Vancouver
Lin Y, Zheng Z, Lin W, Peng W. Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency. Molecular Genetics & Genomic Medicine. 2024. doi:10.1002/mgg3.70003
BibTeX
@article{Lin2024,
author = {Lin, Yiming and Zheng, Zhenzhu and Lin, Weihua and Peng, Weilin},
title = {Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency},
journal = {Molecular Genetics & Genomic Medicine},
year = {2024},
doi = {10.1002/mgg3.70003}
}
EUVIMED